{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:02:30Z","timestamp":1782126150979,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2022YFC2705302"],"award-info":[{"award-number":["2022YFC2705302"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06723-1","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T02:34:53Z","timestamp":1762828493000},"page":"6013-6020","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["From pharmacokinetic-guided FVIII prophylaxis to low-dose Emicizumab prophylaxis: a pilot study revealed a flush of hope"],"prefix":"10.1007","volume":"104","author":[{"given":"Juan","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1641-1472","authenticated-orcid":false,"given":"Kun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"issue":"8","key":"6723_CR1","doi-asserted-by":"publisher","first-page":"542","DOI":"10.7326\/M19-1208","volume":"171","author":"A Iorio","year":"2019","unstructured":"Iorio A, Stonebraker JS, Chambost H et al (2019) Establishing the prevalence and prevalence at birth of hemophilia in males a meta-analytic approach using national registries. Ann Intern Med 171(8):542\u2013546","journal-title":"Ann Intern Med"},{"issue":"S6","key":"6723_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A et al (2020) WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia 26(S6):1\u2013158","journal-title":"Haemophilia"},{"issue":"9","key":"6723_CR3","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/j.jtha.2024.06.002","volume":"22","author":"F N\u00ed \u00c1inle","year":"2024","unstructured":"N\u00ed \u00c1inle F, DiMichele D, Falck-Ytter Y et al (2024) ISTH clinical practice guideline for treatment of congenital hemophilia A and B based on the grading of recommendations assessment, development, and evaluation methodology: considerations for practice management and implementation. J Thromb Haemost 22(9):2404\u20132409","journal-title":"J Thromb Haemost"},{"issue":"5","key":"6723_CR4","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjh.16704","volume":"190","author":"R Rayment","year":"2020","unstructured":"Rayment R, Chalmers E, Forsyth K et al (2020) Guidelines on the use of prophylactic factor replacement for children and adults with haemophilia A and B. J Haematol 190(5):684\u2013695Br","journal-title":"J Haematol"},{"issue":"77","key":"6723_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3109\/ort.1965.36.suppl-77.01","volume":"Suppl","author":"A Ahlberg","year":"1965","unstructured":"Ahlberg A (1965) Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl Suppl(77):3\u2013132","journal-title":"Acta Orthop Scand Suppl"},{"issue":"December 2021","key":"6723_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.thromres.2022.03.008","volume":"213","author":"K Huang","year":"2022","unstructured":"Huang K, Wang Y, Zhen Y et al (2022) Inter-individual variability in pharmacokinetics and clinical features in pediatric patients with severe hemophilia A. Thromb Res 213(December 2021):71\u201377","journal-title":"Thromb Res"},{"issue":"4","key":"6723_CR7","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1111\/hae.14336","volume":"27","author":"K Huang","year":"2021","unstructured":"Huang K, Zhen Y, Li G et al (2021) Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A. Haemophilia 27(4):e450\u2013e457","journal-title":"Haemophilia"},{"issue":"21","key":"6723_CR8","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","volume":"374","author":"M Shima","year":"2016","unstructured":"Shima M, Hanabusa H, Taki M et al (2016) Factor VIII\u2013mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med 374(21):2044\u20132053","journal-title":"N Engl J Med"},{"issue":"3","key":"6723_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/hae.14755","volume":"29","author":"G Oka","year":"2023","unstructured":"Oka G, Roussel-Robert V, Levivien C et al (2023) Assessment of the clinical perception, quality of life and satisfaction of patients with severe congenital haemophilia A without inhibitor after 1 year of Emicizumab therapy. Haemophilia 29(3):709\u2013715","journal-title":"Haemophilia"},{"issue":"16","key":"6723_CR10","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1182\/blood.2020009217","volume":"137","author":"MU Callaghan","year":"2021","unstructured":"Callaghan MU, Negrier C, Paz-Priel I et al (2021) Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1\u20134 studies. Blood 137(16):2231\u20132242","journal-title":"Blood"},{"issue":"4","key":"6723_CR11","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jtha.2023.12.023","volume":"22","author":"R Patil","year":"2024","unstructured":"Patil R, Shanmukhaiah C, Gogtay NJ et al (2024) Low-dose Emicizumab prophylaxis in patients with severe hemophilia A: a retrospective study bringing new hope for our patients. J Thromb Haemost 22(4):1024\u20131030","journal-title":"J Thromb Haemost"},{"key":"6723_CR12","doi-asserted-by":"crossref","unstructured":"Mao Q, Chen Z, Liu G et al (2024) Real-world use of emicizumab in Chinese children with hemophilia a: retrospective data from a comprehensive care center. Pediatr Investig 244\u2013252","DOI":"10.1002\/ped4.12439"},{"issue":"1","key":"6723_CR13","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/hae.14707","volume":"29","author":"A Chuansumrit","year":"2023","unstructured":"Chuansumrit A, Sirachainan N, Jaovisidha S et al (2023) Effectiveness of monthly low dose Emicizumab prophylaxis without 4-week loading doses among patients with haemophilia A with and without inhibitors: a case series report. Haemophilia 29(1):382\u2013385","journal-title":"Haemophilia"},{"issue":"3","key":"6723_CR14","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/hae.14785","volume":"29","author":"S Bansal","year":"2023","unstructured":"Bansal S, Donners AAMT, Fischer K et al (2023) Low dose Emicizumab prophylaxis in haemophilia A patients: a pilot study from India. Haemophilia 29(3):931\u2013934","journal-title":"Haemophilia"},{"key":"6723_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14635","author":"K Huang","year":"2022","unstructured":"Huang K, Ai D, Li G et al (2022) Individualised prophylaxis based on personalised target trough FVIII level optimised clinical outcomes in paediatric patients with severe haemophilia A. Haemophilia. https:\/\/doi.org\/10.1111\/hae.14635","journal-title":"Haemophilia"},{"issue":"2","key":"6723_CR16","first-page":"e214","volume":"27","author":"I Pekrul","year":"2021","unstructured":"Pekrul I, Pfrepper C, Calatzis G et al (2021) Approximation of Emicizumab plasma levels in emergency situations. Practical Approach Haemophilia 27(2):e214\u2013e220","journal-title":"Practical Approach Haemophilia"},{"issue":"10480","key":"6723_CR17","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S0140-6736(24)02139-1","volume":"405","author":"P Chowdary","year":"2025","unstructured":"Chowdary P, Carcao M, Kenet G et al (2025) Haemoph Lancet 405(10480):736\u2013750","journal-title":"Haemoph Lancet"},{"issue":"2","key":"6723_CR18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/rth2.12305","volume":"4","author":"SE Croteau","year":"2020","unstructured":"Croteau SE, Wheeler AP, Khan O et al (2020) Pharmacokinetic-tailored approach to hemophilia prophylaxis: medical decision making and outcomes. Res Pract Thromb Haemost 4(2):326\u2013333","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"6723_CR19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1055\/s-0040-1717114","volume":"121","author":"C Schmitt","year":"2021","unstructured":"Schmitt C, Adamkewicz JI, Xu J et al (2021) Pharmacokinetics and pharmacodynamics of Emicizumab in persons with hemophilia A with factor VIII inhibitors: HAVEN 1 study. Thromb Haemost 121(3):351\u2013360","journal-title":"Thromb Haemost"},{"issue":"11","key":"6723_CR20","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s40262-021-01042-w","volume":"60","author":"AAMT Donners","year":"2021","unstructured":"Donners AAMT, Rademaker CMA, Bevers LAH et al (2021) Pharmacokinetics and associated efficacy of Emicizumab in humans: a systematic review. Clin Pharmacokinet 60(11):1395\u20131406","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"6723_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2023-072363","volume":"13","author":"A Donners","year":"2023","unstructured":"Donners A, Van Der Zwet K, Egberts ACG et al (2023) DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of Emicizumab in people with haemophilia A. BMJ Open 13(6):1\u20137","journal-title":"BMJ Open"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06723-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06723-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06723-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T02:31:31Z","timestamp":1764729091000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06723-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":21,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["6723"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06723-1","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Ethics Committee of First Affiliated Hospital of Zhejiang University(2025-05-EMI), which also approved a consent waiver.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement\u00a0and patient consent statement"}},{"value":"No AI used.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI in scientific writing"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}}]}}